TBIO - Translate Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.75
+0.47 (+5.06%)
As of 12:32PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close9.28
Open9.59
Bid9.73 x 1300
Ask9.85 x 800
Day's Range9.32 - 10.00
52 Week Range4.81 - 16.10
Volume71,306
Avg. Volume201,598
Market Cap496.3M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.06
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.80
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Translate Bio Appoints George Demetri, M.D., to its Board of Directors

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of George D. Demetri, M.D., a physician-scientist at the Dana-Farber Cancer Institute (DFCI), and a professor of medicine at Harvard Medical School to its Board of Directors. “We are honored to have Dr. Demetri join our Board of Directors as we advance our second program into the clinic,” said Ronald Renaud, chief executive officer of Translate Bio.

  • Benzinga26 days ago

    FDA Lifts Clinical Hold On Translate Bio's Liver Disorder Trial

    Shares of the clinical-stage mRNA therapeutics company Translate Bio Inc (NASDAQ: TBIO ), which went public in June 2018, were showing some strength Wednesday.  What Happened Translate Bio said Wednesday ...

  • GlobeNewswire26 days ago

    Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a single-ascending dose (SAD) Phase 1/2 clinical trial of MRT5201 in adult patients with ornithine transcarbamylase (OTC) deficiency. MRT5201 is a first-in-class treatment designed to directly address the underlying cause of OTC deficiency by providing mRNA encoding the fully functional OTC enzyme in patients with the disease. “We are very pleased to be able to move forward with this first-in-human clinical trial of MRT5201 in patients with OTC deficiency,” said Ronald Renaud, chief executive officer, Translate Bio.

  • MIT gene-therapy spinout raises $6M, enters competitive mRNA field
    American City Business Journals2 months ago

    MIT gene-therapy spinout raises $6M, enters competitive mRNA field

    Strand Therapeutics hopes to create treatments using messenger RNA or mRNA, which gives instructions to the body’s cells to create proteins. But the young gene-therapy startup thinks it has created a better method than such players as Moderna Inc. and Translate Bio.

  • GlobeNewswire2 months ago

    Translate Bio to Present at the Jefferies 2019 Healthcare Conference

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will present a corporate overview at the Jefferies 2019 Healthcare Conference in New Yok, NY, on Tuesday, June 4, 2019, at 10:30 a.m. ET. A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

  • GlobeNewswire2 months ago

    Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update

    -- Completed dosing in single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis; data expected 3Q19 -- LEXINGTON, Mass., May 09, 2019 -- Translate Bio.

  • GlobeNewswire3 months ago

    Translate Bio Announces $47.5 Million Private Placement

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced today that it has entered into a securities purchase agreement with several institutional accredited investors for the private placement of 5,582,940 shares of common stock at a purchase price of $8.50 per share, yielding expected gross proceeds of $47.5 million. The private placement is expected to close on or about May 3, 2019, subject to the satisfaction of customary closing conditions. Jefferies and SVB Leerink acted as placement agents to the Company in connection with the private placement.

  • GlobeNewswire3 months ago

    Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

    LEXINGTON, Mass., April 29, 2019 -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially.

  • GlobeNewswire3 months ago

    Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of Robert Plenge, M.D., Ph.D., vice president, research and early development and head of the Inflammation and Immunology Thematic Center of Excellence Unit at Celgene, to its Board of Directors. “On behalf of the Translate Bio team, I’m thrilled to welcome Dr. Plenge to our board of directors,” said Ronald Renaud, chief executive officer, Translate Bio. “My personal mission is to perform discovery research that starts and ends with the patient, and I am grateful to have the opportunity to further pursue this objective by joining Translate Bio’s board of directors,” said Dr. Plenge.

  • GlobeNewswire3 months ago

    Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the presentation of preclinical data for MRT5201, an mRNA therapeutic designed to treat patients with ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder. The poster presentation, entitled “Treatment of Ornithine Transcarbamylase Deficiency with a Targeted mRNA Therapeutic (MRT),” includes data demonstrating that a functional OTC mRNA encapsulated in a lipid nanoparticle (LNP) was successfully delivered to the liver in a preclinical mouse model of OTC deficiency via intravenous (IV) administration.

  • GlobeNewswire3 months ago

    Translate Bio Appoints Richard Wooster as Chief Scientific Officer

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of Dr. Richard Wooster as chief scientific officer.  Dr. Wooster brings more than three decades of experience in pharmaceutical drug discovery and development and academic research, with expertise in genetics, oncology and translational medicine.  In this role, Dr. Wooster will lead Translate Bio’s scientific strategy and research efforts to support current pipeline programs while also identifying and delivering new programs to expand the Company’s pipeline of mRNA therapeutics.

  • GlobeNewswire4 months ago

    Translate Bio Appoints Pasquale (Pat) Sacco as Senior Vice President of Technical Operations

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of Pasquale (Pat) Sacco as senior vice president of technical operations. Mr. Sacco brings more than 30 years of extensive experience in leading technical operations strategy and execution within the biotech and life sciences industries, including manufacturing, supply chain, quality, engineering, technical sciences, and process development.

  • GlobeNewswire4 months ago

    Translate Bio Granted U.S. Patent Relating to Messenger RNA (mRNA) Delivery

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 10,238,754.  This patent, titled “Lipid Nanoparticle Compositions and Methods for mRNA Delivery,” enhances the Company’s current intellectual property by providing coverage for lipid-nanoparticle delivery of encapsulated mRNA where the encoded protein or peptide is secreted and the lipid nanoparticle contains a polyethylene glycol (PEG)-modified lipid. The patent coverage extends to mRNA that is modified or unmodified and to various routes of administration including by intravenous injection, intramuscular injection, or pulmonary delivery.

  • GlobeNewswire4 months ago

    Translate Bio to Participate in Upcoming Investor Conferences

    Guggenheim Healthcare Talks Rare Disease and Genomic Medicines Day: The Company will host one-on-one meetings at the Guggenheim Healthcare Talks Rare Disease and Genomic Medicines Day on Tuesday, April 2, 2019 at Le Meridien in Cambridge, MA. 18th Annual Needham Healthcare Conference: The Company will host one-on-one meetings and give a corporate presentation at 4:10 p.m. Eastern Time at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at the Westin New York Grand Central in New York, NY.  A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio.

  • GlobeNewswire4 months ago

    Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights

    LEXINGTON, Mass., March 21, 2019 -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially.

  • GlobeNewswire4 months ago

    Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the publication of preclinical results demonstrating efficacy in a mouse model of Fabry disease using a lipid nanoparticle (LNP) formulation for systemic delivery of mRNA derived from the Company’s mRNA therapeutic (MRT) platform. Fabry disease is a rare inherited disorder caused by a deficiency of α-galactosidase A. The disease is progressive, destructive and potentially life-threatening. The paper, published in the journal Molecular Therapy and titled Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy, reported the sustained expression of human α-galactosidase (GLA) protein via LNP-formulated mRNA in mice and non-human primates.

  • GlobeNewswire5 months ago

    Translate Bio to Present at the 39th Annual Cowen and Company Healthcare Conference

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will present a corporate overview at the 39th Annual Cowen and Company Healthcare Conference on Monday, March 11, 2019, at 12:00 p.m. ET at the Boston Marriott Copley Place. A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

  • GlobeNewswire5 months ago

    Translate Bio Provides Updates on Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Programs

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today provided an update on its lead clinical candidate, MRT5005, currently in development for the treatment of cystic fibrosis (CF), and on its second product candidate, MRT5201, in development for the treatment of ornithine transcarbamylase (OTC) deficiency. MRT5005, the Company’s lead mRNA product candidate, is designed to treat patients with CF by addressing the underlying cause of the disease regardless of the genetic mutation.

  • GlobeNewswire5 months ago

    Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will present in a session at the 8th Annual SVB Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 11:30 a.m. ET at the Lotte New York Palace in New York. A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcast will be archived on the Company's website for 30 days following the presentation. Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

  • Moderna's Hot New mRNA Technology Has Competition
    Motley Fool6 months ago

    Moderna's Hot New mRNA Technology Has Competition

    They're largely flying under the radar of most investors.

  • GlobeNewswire6 months ago

    Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the Company has received verbal notification from the U.S. Food and Drug Administration (FDA) that the Agency has completed its review of the Company’s Investigational New Drug Application (IND) submission for MRT5201 for the treatment of ornithine transcarbamylase (OTC) deficiency and has additional clinical and nonclinical questions. The Company submitted the IND in December 2018 to support the initiation of a Phase 1/2 clinical trial in patients with OTC deficiency.

  • GlobeNewswire7 months ago

    Translate Bio Advances Programs in Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced several updates relating to its two lead mRNA product candidates in development for the treatment of cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency.

  • GlobeNewswire7 months ago

    Translate Bio Appoints Robert Meyer, MD, to its Board of Directors

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of Robert J. Meyer, MD, a pulmonologist and Principal of Greenleaf Health’s Drug and Biological Products team, to its Board of Directors. “We are thrilled to have Dr. Meyer join our Board of Directors as we seek to advance our first-in-class clinical and preclinical mRNA product candidates,” said Ronald Renaud, chief executive officer of Translate Bio. Dr. Meyer has twenty-five years of regulatory and academic leadership experience.

  • Should You Avoid Translate Bio, Inc. (TBIO)?
    Insider Monkey7 months ago

    Should You Avoid Translate Bio, Inc. (TBIO)?

    Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. […]